← Leaderboards
Mitch A Phelps
Ohio State University
$6,387,631
Attributed
$13,735,461
Total exposure
11
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2013–25$2.5M$1.9M$1.3M$625K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,735,461 · 11
By mechanism
R01$7,839,664 · 3
UH3$1,631,974 · 1
UH2$1,480,302 · 1
P30$1,158,106 · 3
U24$999,988 · 1
R21$372,882 · 1
Top collaborators
- Thomas D Schmittgen8 shared
- Craig C. Hofmeister7 shared
- Flavia Pichiorri7 shared
- Natarajan Muthusamy5 shared
- Christopher C. Coss4 shared
- Thomas A Mace4 shared
- Dwight H. Owen4 shared
- Jan Hendrik Beumer2 shared
Most similar at Ohio State University
Same institution · by research overlap
- Jennifer A. Woyach$6,733,332
- Natarajan Muthusamy$5,466,792
- Kerry Anne Rogers$1,321,382
- Robert J. Lee$4,187,594
- Dwight H. Owen$1,210,636
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsMalignant NeoplasmsFuturePharmacodynamicsDrug KineticsClinical TrialsProteinsValidationNeoplastic CellCellsPharmacodynamic ModelDoseResistanceCancer CellDrug DevelopmentIn VivoIn VitroDesignRegimenNovel TherapeuticsTumorLeukemiaBaseDrug Delivery Systems
Grant awards (43)
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer$1,263,739
R01 · FY2025 · CA · contact PI
The Chesapeake-Ohio Pharmacokinetics Core for The ETCTN$510,158
U24 · FY2025 · CA
Clinical and Translational Data Science Training Program$252,545
T32 · FY2025 · TR
Shared Resource 13: Pharmaco Analytical (PhASR)$131,561
P30 · FY2025 · CA · contact PI
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer$594,010
R01 · FY2024 · CA · contact PI
The Chesapeake-Ohio Pharmacokinetics Core for The ETCTN$489,830
U24 · FY2024 · CA
Shared Resource 13: Pharmaco Analytical (PhASR)$133,823
P30 · FY2024 · CA · contact PI
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer$615,393
R01 · FY2023 · CA · contact PI
Shared Resource 13: Pharmaco Analytical (PhASR)$133,825
P30 · FY2023 · CA · contact PI
Cachexia-mediated FcRn Modulation and Its Impact on Anti-PD1 Therapy in Lung Cancer$639,862
R01 · FY2022 · CA · contact PI
Shared Resource 13: Pharmaco Analytical (PhASR)$133,825
P30 · FY2022 · CA · contact PI
Shared Resource 13: Pharmaco Analytical (PhASR)$133,825
P30 · FY2021 · CA · contact PI
Overcoming IMiD resistance in Myeloma$478,259
R01 · FY2020 · CA · contact PI
Pharmacoanalytical Shared Resource$88,032
P30 · FY2020 · CA · contact PI
Overcoming IMiD resistance in Myeloma$443,589
R01 · FY2019 · CA · contact PI
Phosphatase activation as therapeutic strategy for Chronic lymphocyic leukemia$424,526
R01 · FY2019 · CA
Pharmacoanalytical Shared Resource$92,632
P30 · FY2019 · CA · contact PI
Overcoming IMiD resistance in Myeloma$70,589
R01 · FY2019 · CA · contact PI
Overcoming IMiD resistance in Myeloma$468,343
R01 · FY2018 · CA · contact PI
Phosphatase activation as therapeutic strategy for Chronic lymphocyic leukemia$437,656
R01 · FY2018 · CA
Pharmacoanalytical Shared Resource$99,083
P30 · FY2018 · CA · contact PI
Pharmacoanalytical Shared Resource$4,572
P30 · FY2018 · CA · contact PI
Pharmacoanalytical Shared Resource$2,401
P30 · FY2018 · CA · contact PI
Pharmacoanalytical Shared Resource$2,392
P30 · FY2018 · CA · contact PI
Pharmacoanalytical Shared Resource$2,023
P30 · FY2018 · CA · contact PI
Targeted delivery of microRNA-loaded microvesicle for cancer therapy$768,797
UH3 · FY2017 · TR
Overcoming IMiD resistance in Myeloma$468,343
R01 · FY2017 · CA · contact PI
Phosphatase activation as therapeutic strategy for Chronic lymphocyic leukemia$437,656
R01 · FY2017 · CA
Pharmacoanalytical Shared Resource$80,411
P30 · FY2017 · CA · contact PI
Targeted delivery of microRNA-loaded microvesicle for cancer therapy$800,677
UH3 · FY2016 · TR
Overcoming IMiD resistance in Myeloma$487,331
R01 · FY2016 · CA
Phosphatase activation as therapeutic strategy for Chronic lymphocyic leukemia$437,656
R01 · FY2016 · CA
Overcoming IMiD resistance in Myeloma$135,056
R01 · FY2016 · CA
Pharmacoanalytical Shared Resource$119,701
P30 · FY2016 · CA · contact PI
Targeted delivery of microRNA-loaded microvesicle for cancer therapy$62,500
UH3 · FY2016 · TR
Phosphatase activation as therapeutic strategy for Chronic lymphocyic leukemia$437,656
R01 · FY2015 · CA
Targeted delivery of microRNA-loaded microvesicle for cancer therapy$380,094
UH2 · FY2015 · TR
Targeted delivery of microRNA-loaded microvesicle for cancer therapy$50,000
UH2 · FY2015 · TR
Targeted delivery of microRNA-loaded microvesicle for cancer therapy$487,017
UH2 · FY2014 · TR
Optimizing selective in vivo inhibition of pancreatic tumor JAK2/STAT3 signaling$167,613
R21 · FY2014 · CA · contact PI
Targeted delivery of microRNA-loaded microvesicle for cancer therapy$63,192
UH2 · FY2014 · TR
Targeted delivery of microRNA-loaded microvesicle for cancer therapy$499,999
UH2 · FY2013 · TR
Optimizing selective in vivo inhibition of pancreatic tumor JAK2/STAT3 signaling$205,269
R21 · FY2013 · CA · contact PI